Merck & Company (MRK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Akash Tewari from Jefferies maintained a Buy rating on the stock and has a $138.00 price target.
Akash Tewari’s rating is based on several promising factors for Merck & Company’s stock. A key aspect is the positive feedback from Dr. Ali Ataya, a leading prescriber of Winrevair, who reports significant success with the drug in treating pulmonary arterial hypertension (PAH) patients. The drug’s penetration is expected to grow substantially, with projections indicating a rise in patient usage in the coming years, which suggests a strong market potential.
Furthermore, the ZENITH and HYPERION trial results have been favorable, indicating broad benefits for both late and early PAH patients, potentially leading to increased adoption of Winrevair. Safety data from real-world use has shown fewer adverse events compared to clinical trials, enhancing the drug’s appeal. These factors collectively contribute to a positive outlook for Merck’s stock, justifying the Buy rating.
Tewari covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Pfizer. According to TipRanks, Tewari has an average return of 10.3% and a 50.56% success rate on recommended stocks.
In another report released on February 12, Guggenheim also reiterated a Buy rating on the stock with a $115.00 price target.